Jul. 2 at 5:10 PM
$VALN $5.25 ask. BUY/10X ADD TO LONG POSITION to reset net cost at
$5.85. RETAIN EXIT AT
$25.00 (long trem).
OVERVIEW: In March 2026, VALN referred topline results from the Phase 3 VALOR trial of its Lyme disease vaccine candidate PF-07307405.; missed on statistical significance, noting 73.2% efficacy at 28 days post-dose did not meet the required threshold on the lower bound of the confidence interval. Afterwards, Pfizer and Valneva SE (announced the topline reults from the Phase 3 VALOR trial showing 73.2% efficacy from 28 days post-dose and 74.8% efficacy from one day post-dose in reducing confirmed Lyme disease cases versus placebo. Pfizer and Valneva have said that fewer cases than expected were recorded, and the first pre-specified statistical criterion was not met, but noted the second analysis showed a confidence interval lower bound above 20, supporting plans for regulatory submissions.
